
MannKind (MNKD) Stock Forecast & Price Target
MannKind (MNKD) Analyst Ratings
Bulls say
MannKind is a company with a strong pipeline of potential new therapies and a diverse portfolio of already commercialized products. They have demonstrated success in the market with their current offerings and are continuing to innovate with MNKD-201's Phase 1b data expected in 3Q26, the potential FUROSCIX ReadyFlow launch in 7/26/26, and multiple other catalysts in 2026. With a solid cash position, a potential successful launch of Afrezza in the pediatric market could provide significant upside to consensus expectations and position Afrezza as their most important growth driver.
Bears say
MannKind is facing potential erosion in Tyvaso DPI royalty, despite the market pricing in revenue growth from this product. The company's stock remains significantly undervalued, with risks including commercial execution, clinical trial and regulatory risks, as well as the possibility of a partner controlling one of the company's primary drivers for valuation. Overall, due to these factors, analysts have a negative outlook on MannKind's stock and foresee challenges in the company's performance in the near future.
This aggregate rating is based on analysts' research of MannKind and is not a guaranteed prediction by Public.com or investment advice.
MannKind (MNKD) Analyst Forecast & Price Prediction
Start investing in MannKind (MNKD)
Order type
Buy in
Order amount
Est. shares
0 shares